Cadrenal Cash vs Total Current Liabilities Analysis
| CVKD Stock | 14.01 0.49 3.38% |
Cadrenal Therapeutics, financial indicator trend analysis is way more than just evaluating Cadrenal Therapeutics, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cadrenal Therapeutics, is a good investment. Please check the relationship between Cadrenal Therapeutics, Cash and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cadrenal Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
Cash vs Total Current Liabilities
Cash vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cadrenal Therapeutics, Cash account and Total Current Liabilities. At this time, the significance of the direction appears to have pay attention.
The correlation between Cadrenal Therapeutics,'s Cash and Total Current Liabilities is -0.97. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Cadrenal Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Cadrenal Therapeutics,'s Cash and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Cadrenal Therapeutics, Common are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Cash i.e., Cadrenal Therapeutics,'s Cash and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.97 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Cash
Cash refers to the most liquid asset of Cadrenal Therapeutics,, which is listed under current asset account on Cadrenal Therapeutics, Common balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Cadrenal Therapeutics, customers. The amounts must be unrestricted with restricted cash listed in a different Cadrenal Therapeutics, account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Total Current Liabilities
Total Current Liabilities is an item on Cadrenal Therapeutics, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cadrenal Therapeutics, Common are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Cadrenal Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cadrenal Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cadrenal Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. As of November 22, 2024, Selling General Administrative is expected to decline to about 2.8 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 9.5 M
| 2010 | 2023 | 2024 (projected) | Interest Expense | 107.1K | 17.1K | 16.2K | Depreciation And Amortization | 1.3K | 2.0K | 1.8K |
Cadrenal Therapeutics, fundamental ratios Correlations
Click cells to compare fundamentals
Cadrenal Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cadrenal Therapeutics, is a strong investment it is important to analyze Cadrenal Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cadrenal Therapeutics,'s future performance. For an informed investment choice regarding Cadrenal Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cadrenal Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.73) | Return On Assets (0.71) | Return On Equity (1.25) |
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.